Eli Lilly Finds Bigger Weight-Loss Drug Opportunity
LLY
NVO
Eli LillyLLYis giving investors a potentially important new argument for broader Zepbound coverage: the blockbuster obesity drug may offset a meaningful portion of its cost by reducing other healthcare spending. A real-world study of more than 15,000 adults over age 55 found sustained Zepbound use was associated with sharply lower healthcare costs over time, strengthening Lilly’s case with Medicare, employers and other payers
The study used de-identified U.S. insurance claims from Komodo’s Healthcare Map and compared patients who started Zepbound between November 2023 and September 2025 with individuals who received neither GLP-1 nor GIP/GLP-1 therapies
Excluding the price of Zepbound itself, patients who remained on treatment had average monthly healthcare costs up to 15% lower after six months and 38% lower after 12 months than untreated patients
That distinction matters for Lilly because reimbursement remains one of the biggest constraints on the obesity-drug market. Wider coverage could dramatically expand the addressable population for Zepbound, particularly among older Americans
Lilly estimates Zepbound-related savings reached as much as $181 per patient by six months. That compares with a roughly $195 monthly treatment cost under Medicare’s GLP-1 Bridge program, suggesting other healthcare savings could offset much of the government’s drug expenditure
As coverage expands across Medicare, states, and employers, these data offer evidence on the cost implications of long-term obesity treatment and should help shape decisions, Lilly USA head Ilya Yuffa said
The findings also strengthen Lilly’s competitive position against Novo NordiskNVO, whose Wegovy is included in the same Medicare program
The biggest implication is not the study itself but whether payers use evidence like this to justify broader and more durable obesity-drug coverage. Investors should watch Zepbound prescription growth, patient persistence and reimbursement expansion across Medicare, Medicaid and employer plans. The investment case strengthens if real-world savings continue rising with longer treatment durations, reducing payer resistance to GLP-1 costs. Conversely, weaker persistence, reimbursement restrictions or evidence that total spending remains elevated after including drug costs could limit the commercial benefit. Coverage decisions could ultimately determine how much of Lilly’s enormous obesity opportunity converts into sustained revenue.
GuruFocusStrategy, business, and productsUS stocks
Read more from GuruFocus
